Teligent — JP Morgan Healthcare Conference 2018
15 slides from Teligent's conference presentation, Jan 10, 2018

Slide 1: JP Morgan Healthcare Conference January 10, 2018
JP Morgan Healthcare Conference January 10, 2018 Jason Grenfell-Gardner │CEO Nasdaq Global Select: TLGT

Slide 2: Safe Harbor
Safe Harbor 1 Except for historical facts, the statements in this presentation, as well as oral statements or other written statements made or to be made by Teligent, Inc., are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and involve risks and

Slide 3: Key Investment Highlights
Key Investment Highlights Teligent is a “market disruptor” in alternative dosage form generics Focused on Topical, Injectable, Complex and Ophthalmic (TICO) markets Led by a proven and dynamic management team Significant investment in R&D has resulted in a high-value pipeline State of the art topica

Slide 4: Teligent at-a-glance
Teligent at-a-glance 3 Teligent is a high-growth generics company that develops and markets a diversified product portfolio focused on alternative dosage forms Diversified Product Portfolio • 58 products sold throughout North America − 28 injectables and topicals in US − 30 injectables in Canada Dee

Slide 5: Alternative dosage form generics are susceptible to market disruption
• Limited API supply • Complex formulations • Specialized manufacturing requirements • Fewer market players compared to commoditized dosage forms, such as oral solids • Frequent supply disruptions = more opportunities • Ability to foresee and quickly react to disruptions − Broad portfolio − Robust d

Slide 6: Teligent is focused on Topical, Injectable, Complex and Ophthalmic (TICO) markets
Teligent is focused on Topical, Injectable, Complex and Ophthalmic (TICO) markets 5 Dosage Form Description Current Teligent Strength Topical • Core strength • Established development and manufacturing capabilities • 24 commercial products; 30 filed ANDAs Injectable • Investing in manufacturing – fi

Slide 7: Led by a proven and dynamic executive leadership team
Led by a proven and dynamic executive leadership team 6 Jason Grenfell-Gardner President & Chief Executive Officer Jenniffer Collins Chief Financial Officer Steve Richardson Chief Scientific Officer Martin Wilson General Counsel

Slide 8: Teligent has historically made outsized investments in R&D
Future R&D • Historical R&D spend as a percent of revenue has been far greater than the industry average • R&D as a percent of revenue will decline going forward • Accelerate development throughput − Leverage previously approved ANDAs/NDAs, including 23 injectables − Accelerated path to market via P

Slide 9: R&D investment has resulted in a deep, high-value pipeline
R&D investment has resulted in a deep, high-value pipeline 8 Cumulative US ANDA Submissions and Approvals As of December 31, 2017 8 13 19 31 36 32 1911 2012 2013 20172016 2 2014 1 2015 Pending ANDAsApproved ANDAs % Total Addressable Market of US Submissions 100% = ~$2.0 billion* GDUFA Year 3-5 10% P

Slide 10: Declining ANDA review cycle times bodes well for near-term pipeline approvals
Declining ANDA review cycle times bodes well for near-term pipeline approvals 9 2022 39 GDUFA Yr 5 GDUFA Yr 3 GDUFA Yr 4 Pre- GDUFA Yr 3 57 33 22 11 1 GDUFA Yr 5 Pre- GDUFA Yr 3 GDUFA Yr 3 GDUFA Yr 4 Average ANDA Approval Times Months Average Open ANDA Submission Times Months Average review times fo

Slide 11: Robust topical and injectable manufacturing infrastructure
Robust topical and injectable manufacturing infrastructure 10 Investing ~$55M in the facility expansion Background • Located in Buena, New Jersey • Currently manufacture 24 Teligent- label topical products • Facility expansion >3x original plant − Now almost 110,000 square feet − Increased topical c

Slide 12: Strong sales growth has subsidized investment for sustained growth
Strong sales growth has subsidized investment for sustained growth 11 $52 $66 $44 $32 $18 $2 $10 $3 $6 $1 2013 20152014 Q1-Q3 20172016 Annual Financial Performance $, Millions Adj. EBITDANet Revenue Full Year 2017 Net Revenue Guidance $65-67* * Guidance as of November 6, 2017

Slide 13: Teligent-label product sales have exhibited strong growth
Teligent-label product sales have exhibited strong growth 12 49 32 20 7 2014 20152013 2016 CAGR +88% Annual Teligent-Label Product Net Sales $, Millions Key Growth Drivers: • 19 Teligent-label products launched in US since 2012 − Launched first Teligent-label product in December 2012 • Acquired econ

Slide 14: Solid foundation to support sustainable, profitable growth
Solid foundation to support sustainable, profitable growth Focus on Investment 2012 - 2017 Focus on Profitability 2018 and beyond • Invested >$150M* over the past 5 years • Transitioned from contract services to Teligent-label products • Strengthened development capabilities and grew product pipelin

Slide 15: Key 2018 Objectives
Key 2018 Objectives 14 • Enhance profitability − Disciplined cost control • Increase development throughput − Leverage previously launched ANDAs/NDAs • Accelerate ANDA approvals − 11 ANDAs with GDUFA goal dates in 1Q and 2Q • Strengthen commercial presence − Expand commercial team – enhance retail a
Source: SEC EDGAR · 8-K filed Jan 10, 2018
More decks from Teligent Inc
35th Annual J.P. Morgan Healthcare Conference (January 2017)20 slides · Jan 11, 2017
IGI Laboratories — Shareholder Meeting (June 2014)15 slides · Jun 4, 2014
IGI Laboratories — 25th Annual Roth Conference 201314 slides · Mar 20, 2013
IGI Laboratories — Investor Presentation (July 2012)14 slides · Jul 9, 2012
IGI — Shareholder Meeting (May 2008)18 slides · May 12, 2008